Lipocine up as post-partum depression drug shows promising results in early stage study

Lipocine

10/10/2024 14:39

** Shares of drug developer Lipocine  LPCN.O  up 6.19% at
$5.5 in premarket trading
    ** Administration of Oral brexanolone, co's drug for
treating post-partum depression, was consistent with therapies
effective in managing depression, anxiety, tremors, and seizures
    **Oral brexanolone was well-tolerated in the Phase 1 study,
with a safety profile consistent with previous clinical studies
    ** As of last close stock up 85.30% YTD

 (Reporting by Khusbu Jena)
 ((Khusbu.Jena@thomsonreuters.com;))